Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Chester

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Nature Medicine|December 11, 2007
Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapyJian Qiao, Timothy Kottke, Candice Willmon, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 2, 2008
Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancerTimothy Kottke, Rosa M Diaz, Karen Kaluza, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 16, 2009
A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]Prashant Patel, J Graham Young, Vivien Mautner, et al.
Investigational New Drugs|January 19, 2013
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancerRobert Jones, Jacqueline Vuky, Tony Elliott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2024
Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT TrialAlison Jane Birtle, Robert Jones, John Chester, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder CancerThomas Powles, Robert A Huddart, Tony Elliott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2012
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignanciesEleni M Karapanagiotou, Victoria Roulstone, Katie Twigger, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2017
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-lossSimon J Crabb, Karen Martin, Julia Abab, et al.
Lancet (London, England)|March 9, 2020
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trialAlison Birtle, Mark Johnson, John Chester, et al.
Therapeutic Advances in Medical Oncology|September 9, 2021
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspectiveGehan Soosaipillai, Anjui Wu, Gino M Dettorre, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Nature Medicine|December 11, 2007
Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapyJian Qiao, Timothy Kottke, Candice Willmon, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 2, 2008
Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancerTimothy Kottke, Rosa M Diaz, Karen Kaluza, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 16, 2009
A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]Prashant Patel, J Graham Young, Vivien Mautner, et al.
Investigational New Drugs|January 19, 2013
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancerRobert Jones, Jacqueline Vuky, Tony Elliott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2024
Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT TrialAlison Jane Birtle, Robert Jones, John Chester, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder CancerThomas Powles, Robert A Huddart, Tony Elliott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2012
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignanciesEleni M Karapanagiotou, Victoria Roulstone, Katie Twigger, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2017
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-lossSimon J Crabb, Karen Martin, Julia Abab, et al.
Lancet (London, England)|March 9, 2020
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trialAlison Birtle, Mark Johnson, John Chester, et al.
Therapeutic Advances in Medical Oncology|September 9, 2021
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspectiveGehan Soosaipillai, Anjui Wu, Gino M Dettorre, et al.
Pageof 4